Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck’s CEO recently shared insights on minimal impacts from EU tariffs and highlighted challenges in Gardasil production.

Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring ...

Robert F. Kennedy Jr. announces plans to reform the Vaccine Injury Compensation Program, addressing claims of inefficiency ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Merck's Q2 2025 earnings call reveals revenue of $15.8B, strategic growth plans with a $3B reinvestment initiative, and confidence in driving ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck did not immediately respond to a request for comment on the job cuts. The company expects the program to cost about $3 billion to implement but would lead to $3 billion in annual cost savings by ...

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...

Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...